A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients

Annals of Oncology

Volumn 12, Issue 11, 2001, Pages 1567-1573

  Huisman, C ^a   Postmus, P E ^a   Giaccone, G ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Etoposide; Lung cancer; NSCLC; SCLC; Topoisomerase inhibitors; Topotecan

Indexed keywords

ANTIEMETIC AGENT; COLONY STIMULATING FACTOR; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOCYTE COUNT; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MESOTHELIOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CROSS-OVER STUDIES; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; TOPOTECAN; TREATMENT OUTCOME;

EID: 0035692525     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013171928472     Document Type: Article

References (39)

1. Schedule-dependent topoisomerase II-inhibiting drugs
2. Review of phase I clinical studies with topotecan
3. Phase II study of topotecan in metastatic non-small-cell lung cancer
4. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan
5. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small-cell lung cancer
6. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line
7. The significance of the sequence of administration of topotecan and etoposide
8. A phase II study of irinotecan (CPT-11) and etoposide (VP-16) for metastatic non-small-cell lung cancer (NSCLC): Japanese Clinical Oncology Group (JCOG) trial
9. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer
10. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer
11. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
12. Sequential administration of topotecan and etoposide in extensive small-cell lung cancer - A phase I study
13. Guidelines for Reporting Adverse Reactions
14. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells
15. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons
16. Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo
17. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines
18. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines
19. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
20. Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry
21. Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line
22. Reduced topoisomerase II activity in multidrug-resistant human non-small-cell lung cancer cell lines
23. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression
24. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines
25. Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process
26. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro
27. Characterization of high and low level resistance to topoisomerase I poisons in small-cell lung cancer resistant to camptothecin and topotecan
28. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines
29. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors
30. Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small-cell lung cancer: A study of the West Japan Lung Cancer Group
31. A phase I study of a five day drug schedule of intravenous topotecan and etoposide in untreated small-cell lung cancer
32. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide
33. Sequential administration of topotecan and oral etoposide in treatment of small-cell lung cancer
34. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
35. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
36. Small-cell lung cancer and the influence of chemotherapy on CFUcs in bone marrow